Research graph
References from An Environmentally Sensitive Epidermal Growth Factor Receptor Probe for Turn-On Tumor Imaging and TGF-β1-Mediated Cancer Immunotherapy via the Selective Depletion of TI-Tregs. Local targets link to admitted publications; unresolved targets remain external evidence.
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
10.1186/s13045-022-01311-6 · 2022 · External reference
Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review
10.1016/j.bbcan.2023.188927 · 2023 · External reference
Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor
10.1124/pharmrev.123.000906 · 2023 · External reference
Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling
10.1038/s41467-023-38390-z · 2023 · External reference
Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment
10.1016/j.jconrel.2022.07.018 · 2022 · External reference
Non-invasive ultra-sensitive detection of breast cancer biomarker using cerium nanoparticle functionalized graphene oxide enabled impedimetric aptasensor
10.1016/j.bios.2024.116925 · 2025 · External reference
Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment
10.1038/s41467-024-55378-5 · 2025 · External reference
Epidermal Growth Factor Receptor (EGFR)-Targeting Peptides and Their Applications in Tumor Imaging Probe Construction: Current Advances and Future Perspectives
10.3390/biology14081011 · 2025 · External reference
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
10.2174/1568026620666200303123102 · 2020 · External reference
Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
10.1016/j.pharmr.2025.100076 · 2025 · External reference
EGFR signaling pathway as therapeutic target in human cancers
10.1016/j.semcancer.2022.04.002 · 2022 · External reference
The Role of EREG/EGFR Pathway in Tumor Progression
10.3390/ijms222312828 · 2021 · External reference
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer
10.1016/j.ccell.2023.12.002 · 2024 · External reference
Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation
10.1016/s0165-2478(02)00023-8 · 2002 · External reference
The Effects of Anti-TGF-β1 on Epithelial-Mesenchymal Transition in the Pathogenesis of Adenomyosis
10.1007/s43032-020-00139-0 · 2020 · External reference
Suppression of TGF-β/Smad2 signaling by GW788388 enhances DENV-2 clearance in macrophages
10.1002/jmv.27879 · 2022 · External reference
Selective targeting or reprogramming of intra-tumoral Tregs
10.1007/s12032-024-02300-0 · 2024 · External reference
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors
10.1038/s41467-022-30258-y · 2022 · External reference
Discovery of EGFR-Targeted Environment-Sensitive fluorescent probes for cell imaging and efficient tumor detection
10.1016/j.bioorg.2021.105585 · 2022 · External reference
A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding
10.1002/ange.201909536 · 2019 · External reference
Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites
10.1016/j.bmc.2023.117534 · 2023 · External reference
Synthetic fluorophores for live-cell fluorescence microscopy and biosensing
10.1038/s41589-025-02038-4 · 2025 · External reference
Emission tuning of fluorescent kinase inhibitors: conjugation length and substituent effects
10.1021/jo500520x · 2014 · External reference
Characterization of skin adverse events associated with cetuximab: real-world insights from the two global pharmacovigilance databases of FAERS and VigiAccess
10.3389/fonc.2026.1768984 · 2026 · External reference
Real-World Safety of Anti-EGFR Antibodies: 20-Year Analysis from Global Pharmacovigilance Databases
10.7150/ijms.122194 · 2025 · External reference
Reprogramming the immunosuppressive tumor microenvironment through nanomedicine, an immunometabolism perspective
10.1016/j.ebiom.2024.105301 · 2024 · External reference
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
10.1016/j.bbcan.2023.188967 · 2023 · External reference
Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy
10.1172/jci180080 · 2024 · External reference
FOXP3 (in) stability and cancer immunotherapy
10.1016/j.cyto.2024.156589 · 2024 · External reference
Structural changes accompanying intramolecular electron transfer: focus on twisted intramolecular charge-transfer states and structures
10.1021/cr940745l · 2003 · External reference
Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation
10.1038/s41467-021-26352-2 · 2021 · External reference
Transforming growth factor-β1 in regulatory T cell biology
10.1126/sciimmunol.abi4613 · 2022 · External reference
Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
10.1016/j.heliyon.2024.e27531 · 2024 · External reference
Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs)
10.1080/03602532.2024.2388203 · 2024 · External reference
Hepatotoxicity and efficacy associated with first- and new-generation EGFR-TKIs in patients with NSCLC: a systematic review and meta-analysis
10.1186/s12885-025-15330-2 · 2025 · External reference
Precision preclinical modeling to advance cancer treatment
10.1093/jnci/djae249 · 2025 · External reference
The ARRIVE guidelines 2.0: updated guidelines for reporting animal research
10.1371/journal.pbio.3000410 · 2020 · External reference
A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding
10.1002/ange.201909536 · ExternalCitation · doi-reference
Suppression of TGF-β/Smad2 signaling by GW788388 enhances DENV-2 clearance in macrophages
10.1002/jmv.27879 · ExternalCitation · doi-reference
Selective targeting or reprogramming of intra-tumoral Tregs
10.1007/s12032-024-02300-0 · ExternalCitation · doi-reference
The Effects of Anti-TGF-β1 on Epithelial-Mesenchymal Transition in the Pathogenesis of Adenomyosis
10.1007/s43032-020-00139-0 · ExternalCitation · doi-reference
Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review
10.1016/j.bbcan.2023.188927 · ExternalCitation · doi-reference
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
10.1016/j.bbcan.2023.188967 · ExternalCitation · doi-reference
Discovery of EGFR-Targeted Environment-Sensitive fluorescent probes for cell imaging and efficient tumor detection
10.1016/j.bioorg.2021.105585 · ExternalCitation · doi-reference
Non-invasive ultra-sensitive detection of breast cancer biomarker using cerium nanoparticle functionalized graphene oxide enabled impedimetric aptasensor
10.1016/j.bios.2024.116925 · ExternalCitation · doi-reference
Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites
10.1016/j.bmc.2023.117534 · ExternalCitation · doi-reference
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer
10.1016/j.ccell.2023.12.002 · ExternalCitation · doi-reference
FOXP3 (in) stability and cancer immunotherapy
10.1016/j.cyto.2024.156589 · ExternalCitation · doi-reference
Reprogramming the immunosuppressive tumor microenvironment through nanomedicine, an immunometabolism perspective
10.1016/j.ebiom.2024.105301 · ExternalCitation · doi-reference
Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
10.1016/j.heliyon.2024.e27531 · ExternalCitation · doi-reference
Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment
10.1016/j.jconrel.2022.07.018 · ExternalCitation · doi-reference
Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
10.1016/j.pharmr.2025.100076 · ExternalCitation · doi-reference
EGFR signaling pathway as therapeutic target in human cancers
10.1016/j.semcancer.2022.04.002 · ExternalCitation · doi-reference
Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation
10.1016/s0165-2478(02)00023-8 · ExternalCitation · doi-reference
Structural changes accompanying intramolecular electron transfer: focus on twisted intramolecular charge-transfer states and structures
10.1021/cr940745l · ExternalCitation · doi-reference
Emission tuning of fluorescent kinase inhibitors: conjugation length and substituent effects
10.1021/jo500520x · ExternalCitation · doi-reference
Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation
10.1038/s41467-021-26352-2 · ExternalCitation · doi-reference
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors
10.1038/s41467-022-30258-y · ExternalCitation · doi-reference
Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling
10.1038/s41467-023-38390-z · ExternalCitation · doi-reference
Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment
10.1038/s41467-024-55378-5 · ExternalCitation · doi-reference
Synthetic fluorophores for live-cell fluorescence microscopy and biosensing
10.1038/s41589-025-02038-4 · ExternalCitation · doi-reference
Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs)
10.1080/03602532.2024.2388203 · ExternalCitation · doi-reference
Precision preclinical modeling to advance cancer treatment
10.1093/jnci/djae249 · ExternalCitation · doi-reference
Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor
10.1124/pharmrev.123.000906 · ExternalCitation · doi-reference
Transforming growth factor-β1 in regulatory T cell biology
10.1126/sciimmunol.abi4613 · ExternalCitation · doi-reference
Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy
10.1172/jci180080 · ExternalCitation · doi-reference
Hepatotoxicity and efficacy associated with first- and new-generation EGFR-TKIs in patients with NSCLC: a systematic review and meta-analysis
10.1186/s12885-025-15330-2 · ExternalCitation · doi-reference
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
10.1186/s13045-022-01311-6 · ExternalCitation · doi-reference
The ARRIVE guidelines 2.0: updated guidelines for reporting animal research
10.1371/journal.pbio.3000410 · ExternalCitation · doi-reference
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
10.2174/1568026620666200303123102 · ExternalCitation · doi-reference
Characterization of skin adverse events associated with cetuximab: real-world insights from the two global pharmacovigilance databases of FAERS and VigiAccess
10.3389/fonc.2026.1768984 · ExternalCitation · doi-reference
Epidermal Growth Factor Receptor (EGFR)-Targeting Peptides and Their Applications in Tumor Imaging Probe Construction: Current Advances and Future Perspectives
10.3390/biology14081011 · ExternalCitation · doi-reference
The Role of EREG/EGFR Pathway in Tumor Progression
10.3390/ijms222312828 · ExternalCitation · doi-reference
Real-World Safety of Anti-EGFR Antibodies: 20-Year Analysis from Global Pharmacovigilance Databases
10.7150/ijms.122194 · ExternalCitation · doi-reference
